Benzathine Penicillin Does Not Cause Neonatal Cholestasis
Benzathine penicillin G is not a recognized cause of neonatal cholestasis. The drug is widely used and recommended in neonates for treatment and prophylaxis of congenital syphilis, with no documented association with cholestatic liver disease 1, 2.
Evidence from Guidelines and Drug Labels
The CDC guidelines extensively detail benzathine penicillin G use in neonates across multiple scenarios for congenital syphilis treatment, with doses ranging from 50,000 units/kg as a single IM injection to more intensive regimens 1, 2. These guidelines, spanning from 2002 to 2010, recommend:
- Single-dose regimens (50,000 units/kg IM) for low-risk infants with adequate maternal treatment
- 10-day courses for higher-risk scenarios
- Follow-up monitoring including liver function tests when clinically indicated 1
The FDA drug label for benzathine penicillin G lists extensive adverse reactions but does not include cholestasis or hepatobiliary dysfunction 3. Documented adverse effects include hypersensitivity reactions, injection site reactions, and neurological complications—but no hepatic cholestasis 3.
What Actually Causes Neonatal Cholestasis
The research evidence clearly identifies the true culprits of neonatal cholestasis:
- Parenteral nutrition (PN): The most common acquired cause in NICU patients, with incidence of 2.94% in neonates receiving PN >5 days, increasing to 20.7% when PN exceeds 14 days 4, 5
- Intestinal failure-associated liver disease (IFALD): Related to prolonged PN and intestinal dysfunction 6
- Primary liver diseases: Including biliary atresia, progressive familial intrahepatic cholestasis (PFIC), and bile acid synthesis defects—accounting for only 3.8% of NICU cholestasis cases 7, 8
- Prematurity and low birth weight: Independent risk factors for cholestasis development 4, 5
Clinical Context
When evaluating neonatal cholestasis (defined as direct bilirubin ≥20 µmol/L or >20% of total bilirubin), the diagnostic workup should focus on:
- Duration and composition of parenteral nutrition (longer duration and higher carbohydrate loads increase risk) 4, 5
- Intestinal function and feeding tolerance
- Gamma-glutamyl transferase (GGT) levels to differentiate cholestasis subtypes 8
- Primary genetic/metabolic liver diseases in early presenters with specific clinical features 7, 8
Important Caveat
The 2004 AAP guidelines note that phototherapy can cause bronze infant syndrome in neonates with pre-existing cholestasis, but this is a complication of phototherapy in cholestatic infants—not a drug-induced cholestasis 9. This should not be confused with benzathine penicillin causing cholestasis.
Bottom Line
If a neonate receiving benzathine penicillin develops cholestasis, investigate the actual causes: prolonged parenteral nutrition, intestinal failure, prematurity complications, or primary hepatobiliary disease. The penicillin itself is not the culprit and should not be discontinued based on cholestasis alone, particularly when treating congenital syphilis where adequate treatment is critical to prevent serious sequelae 1, 2.